Zobrazeno 1 - 10
of 297
pro vyhledávání: '"Singh, A."'
Autor:
Yongmei Yin, Yunpeng Liu, Rubing Han, Rongsheng Zheng, Shona Nag, Xiaojia Wang, Y Liu, Ying Cheng, Zefei Jiang, Jin Yang, Jing Cheng, Xichun Hu, Tao Sun, MA Coccia Portugal, Man Li, Wanli Zhang, Roberto Hegg, Govindbabu Kanaka Setty, Xi Chen, Neonyana Keorapetse Rebecca Tabane, Qingyuan Zhang, Hongxia Wang, Nalini Kilara, Bernardo Leon Rapoport, Fabio Franke, Romulo Costa, Ashish Singh, Huiping Li, Zhongsheng Tong, Christina Pimentel Oppermann, Harsha Panchal, Yongkui Lu, Gustavo Girotto, Wenjing Hu, Ning Wang, Jifeng Feng, Xinhong Wu, Jyoti Bajpai, Qiang Liu, Min Yan, Jian Huang, Amit Agarwal, Chanchal Goswami, Shiying Yu, Ning Liao, Quchang Ouyang, Jian Liu, Cristiano Souza
Publikováno v:
Cancer Research. 81:PS13-25
Background: In the phase III MONARCH plus study (NCT02763566) the cyclin-dependent kinase (CDK) 4&6 inhibitor abemaciclib in combination with non-steroidal aromatase inhibitors (NSAI) or with fulvestrant compared with placebo demonstrated its efficac
Autor:
Tianyi Tang, Ritesh Parajuli, Min-Ying Su, Chaitali Singh Nangia, Rita S. Mehta, Yu Cheng, Neha Patel
Publikováno v:
Cancer Research. 81:PS5-32
Background: The combination of anastrozole and fulvestrant (A+F) is associated with improvement in overall survival (OS) as compared to anastrozole (A) in patients (pts) with hormone receptor-positive (HR+) breast cancer (BC), specifically in pts wit
Autor:
J. Wu, Constanta Timcheva, L. Menon-Singh, Miguel Martín, Katie Zhou, Guy Jerusalem, Michelino De Laurentiis, Claudio Zamagni, L G Zhukova, Janice Lu, Aleix Prat, Senthil Rajappa, Paul Cottu, Stephen Chia
Publikováno v:
Cancer Research. 81:PS10-05
Background: CompLEEment-1 (NCT02941926) is an ongoing Phase IIIb trial of ribociclib (RIB) in combination with letrozole (LET) in the first-line setting for patients (pts) with HR+, HER2- ABC, reflecting a real-world clinical setting by including a m
Publikováno v:
Cancer Research. 81:PS10-58
Background: Guidelines recommend patients treated with trastuzumab (TRA) undergo a multiple gated-acquisition (MUGA) scan or echocardiogram (ECHO) at baseline and every 3 months thereafter. In this retrospective study, we evaluated the incidence of c
Autor:
Danielle Braun, Jingan Zhou, Kevin S. Hughes, Reem S Chamseddine, Kanhua Yin, Jin Wang, Preeti Singh, Mark E. Robson
Publikováno v:
Cancer Research. 81:PS8-40
Background: Family history is one of the strongest predisposing factors for male breast cancer (MBC). Several MBC susceptibility genes have been identified, but the risk of MBC for individuals with a pathogenic variant in these genes (i.e., penetranc
Publikováno v:
Cancer Research. 81:PS7-84
Background The presence of carcinoma cells in either lymphatic vessels, blood vessels or both is defined as lymphovascular invasion (LVI). The presence of LVI is associated with an increased risk of axillary lymph node and distant metastases. LVI is
Autor:
Keri Stenger, Sheena Singh, Sherko Kümmel, Sara M. Tolaney, Amy Lee Chong, Vanita Tongbram, Pradeep Basa, Valentina Guarneri, Gebra Cuyun Carter, Shivaprasad Singuru, Maitreyee Mohanty
Publikováno v:
Cancer Research. 80:P3-08
Background Advanced breast cancer (ABC) is a heterogeneous disease with several well-defined subtypes, among which, HR+, HER2- is the most prevalent. While clinical factors and genomic signatures have clear prognostic significance in the early breast
Autor:
Ankit Gupta, Sangeeta Aggarwal, Manish Kumar Singh, Guroosh Chaudhary, Sujeet Kumar, Juhi Jha, Rahul Kumar Gond, Alok Aggarwal
Publikováno v:
Cancer Research. 80:P5-11
Addition of a CDK 4/6 inhibitor to endocrine therapy has demonstrated improved clinical outcomes and delayed the onset of tumor progression in patients with metastatic hormone receptor positive (HR+) breast cancer. The following three CDK 4/6 inhibit
Autor:
Margaret Grayson, Rachel O'Connell, Rajiv V. Dave, Stuart McIntosh, Ramsey I. Cutress, Ian Whitehead, Shelley Potter, Sheeba Irshad, Charlotte E. Coles, Abeer M Shaaban, Ellen Copson, Carlo Palmieri, Finian Bannon, Chris Holcombe, J Singh, Nisha Sharma, Gareth Irwin, Ciara S O'Brien
Publikováno v:
Cancer Research. 80:P2-16
Introduction: Potential advantages of neoadjuvant systemic therapy (NST) include downstaging disease to minimise surgery, and in vivo assessment of tumour sensitivity to therapeutic drugs. Considerable variation in NST use remains, however, and it is
Publikováno v:
Cancer Research. 80:P2-16
Background: Trastuzumab and pertuzumab (HP) with standard chemotherapy is approved for use in the neoadjuvant setting. We performed a retrospective analysis of patients (pts) treated with dose-dense doxorubicin and cyclophosphamide (AC) → paclitaxe